ArticleOncology letters2026
Prognostic significance of squamous differentiation in pT2N0 urothelial bladder cancer.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer is the ninth most common malignancy worldwide, with urothelial carcinoma (UC) representing the predominant histopathological subtype. UC may present as pure urothelial carcinoma (PUC), or alongside other variant histologies (VHs), with squamous differentiation in UC (SD) being the most frequently observed variant. The present study provides a population-based insight into the survival outcomes of patients with SD compared with PUC in early-stage disease. The present retrospective, observational study analyzed pathology reports from all cystectomies (n=632) performed at Uludag University Faculty of Medicine (Bursa, Turkey) between December 2010 and December 2023. A total of 23 patients with SD and 45 patients with PUC were evaluated; all of the patients had pathological stage T2N0 (pT2N0). The median follow-up period was 5.27 years (range, 0.23-16.60). Kaplan-Meier survival analysis demonstrated no statistically significant difference in disease-free survival (DFS) or overall survival (OS) between the SD and PUC groups. Univariate Cox regression analysis identified that age at diagnosis was a potential prognostic factor of both DFS and OS. The findings suggest that SD does not significantly affect DFS or OS in patients with pT2N0 UC. However, further prospective, multicenter, large-scale studies are warranted to validate and expand upon these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.